The first batch of Kazakhstani vaccine QazVac (QazCovid-in) against COVID-19 was shipped
Today, Deputy Prime Minister of the Republic of Kazakhstan Yeraly Tugzhanov took part in the shipment of the first batch of the Kazakh vaccine QazVac (QazCovid-in), produced on the basis of the Scientific Research Institute for Biosafety Problems and got acquainted with the construction progress of a biopharmaceutical plant in the village of Gvardeisky, Kordai district, Zhambyl region.
«The creation of a Kazakh vaccine allowed our country to enter the top five countries in the world that have developed their own vaccines against coronavirus infection. This is not only a matter of public health, it is also evidence of the potential of domestic science and the practical application of modern technologies in biopharmaceuticals, the reputation of the state» said Yeraly Tugzhanov.
In October last year, the President of the Republic of Kazakhstan Kassym-Jomart Tokayev gave specific instructions on the development of a domestic vaccine.
The Deputy Prime Minister noted that all the instructions of the Head of State for the production of the Kazakh vaccine are under the special control of the Government, today's release of the first batch of vaccine testifies to their implementation in practice.
The first 50 thousand doses of the QazVac vaccine will be distributed to the SK-Pharmacy hubs and then will be delivered to the warehouses of health departments in all regions of the country. April 26 of this year, vaccination of the population with the QazVac vaccine will begin. In May, it is planned to release the next batch in the amount of 50 thousand doses. Further, the production of the vaccine will be gradually increased to 500-600 thousand doses per month.
The domestic vaccine is included in the register of the World Health Organization. Its complete safety has been proven, the vaccine forms a strong immunity against coronavirus infection. The advantage of an inactivated vaccine is that it does not cause vaccine-associated diseases. In addition, the methods of delivery of the QazVac vaccine do not require complex refrigeration units, they are transported in a refrigerator at a temperature of + 2-8 degrees.
Also, as part of a working trip Yeraly Tugzhanov got acquainted with the construction progress of a biopharmaceutical plant on the basis of the Research Institute. Currently, construction, installation and finishing works have been completed. Work has begun on installation, commissioning and commissioning of equipment with connection to utility networks.
In March of this year, a positive conclusion (DQ) of the study for compliance with GMP standards was received. The next step is to validate and obtain the GMP international standard certificate itself. For these purposes, the Turkish company "Atabay" was involved.
Following the visit to the facility, the Deputy Prime Minister gave a positive assessment and noted that in accordance with the instructions of the Head of State, the construction of a plant for the production of domestic vaccines is being carried out within the specified time frame.
It is noted that after the launch of the biopharmaceutical plant this year the production of the QazVac vaccine will continue on its basis.